Description
Certificate of Analysis
High Performance Liquid Chromatography
Mass Spectrometry
CJC-1295 & Ipamorelin Peptide Blend
Ipamorelin & CJC-1295 are both considered to be growth hormone secretagogues. Ipamorelin is a synthetic pentapeptide, (2) and CJC-1295 peptide consists of 29 amino acids (3). This category of peptides, i.e. growth hormone secretagogues (GSHs), are peptides that are assumed to stimulate the release of the growth hormones, however are not considered growth hormone releasing peptides themselves. Both Ipamorelin and CJC-1295 peptides have been assigned by researchers to this class, studied for similar potential actions and apparently differing only in terms of their half-life and pharmacokinetic profiles.
Overview
CJC-1295 & Ipamorelin peptides both are suggested by researchers to augment the levels of the growth hormones through a possible triggering of the anterior pituitary gland. Scientists consider that once triggered, growth hormones may be naturally secreted, maintaining levels of growth hormones in the organism (5).
CJC-1295 peptide has four amino acid substitutions in its structure which scientists suggest may enhance its activity and resistance towards proteolytic enzymes. Owing to these substitutions, the peptide might be able to bind covalently to blood albumin, with trace amounts possibly able to bind to fibrinogen and immunoglobulin G (IgG) (6). This may lead to elevated levels of plasma growth hormone and insulin-like growth factor 1 (IGF-1).
When the peptide blend, sometimes also called the peptide stack, is presented in combination, research studies typically report that the Ipamorelin exerts initial action, exhibiting some sign of impact within the first two hours (7) of presentation, and as it starts to wean off, the CJC-1295 peptide may gradually supplement action (7). Research studies have studied the peptides alone and in combination for the following potential actions:
- possible improvement in bone density
- possible increase in lean muscle mass
- possible ability to burn fat quickly
- potential increased recovery time from injuries
- potential increased insulin sensitivity
- possible increased energy levels
Research and Clinical Studies
CJC-1295 & Ipamorelin Peptide and Growth Hormone Secretagogues (GSHs)
This clinical study (4) aimed to determine the potential of growth hormone secretagogues. Various GSHs were presented to the test subjects and their physiological changes, if any, were monitored. As an outcome of this long term, rigorous study, it was suggested that GSHs exhibited possible improved growth velocity in younger subjects, possibly stimulating their appetite and improving lean mass in mature subjects. In obese subjects, these peptides appeared to possibly stimulate a reduction in bone turnover, increased lean mass and potentially improved the sleep cycle.
CJC-1295 & Ipamorelin Peptide and Half Life Determination
Additional clinical studies have been conducted on test subjects to determine the half life of and individual pharmacokinetic profiles of the two peptides. In one late 1990s study (7), a clinical trial was conducted on 8 male test subjects with a concentration escalation design. The level of growth hormones was monitored after every instance of peptide presentation. At the end of the study, it was suggested by the researchers that there was a single episode of growth hormone release with the highest peak at 0.67 hours, after which there was an exponential decline up to negligible concentrations of the growth hormone. This study concluded that the Ipamorelin peptide appeared to exhibit a short half-life of 2 hours, after which the potential peptide action appears to begin to decline.
CJC-1295 Peptide General Research
In this early 2000s study (8), a clinical trial was conducted on male test subjects aged between 20 and 40 years old. Test subjects were divided into two groups; one group was presented with the placebo and the other with the peptide. Blood was sampled out from the subjects one week before and after the presentation of CJC-1295 peptide (and placebo) to monitor the levels of growth hormone pulsatility. At the end of the study, it was suggested that CJC-1295 contributed to a 7.5-fold increase in the growth hormone pulsatility levels as compared to that of the placebo.
CJC-1295 & Ipamorelin peptide blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
References:
1. A Giustina, JD Veldhius, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human, Endocrinology, 1 December 1998,
2. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
3. Lucie Jette et al, hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog, ResearchGate, January 2005. https://www.researchgate.net/publication/228484039
4. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/
5. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822 https://pubmed.ncbi.nlm.nih.gov/9849822/
6. The Discovery of Growth Hormone-Releasing Hormone: An Update https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01740.x
7. Gobburu JV, Agersø H, Jusko WJ, Ynddal L (September 1999). “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers”. Pharmaceutical Research. 16 (9): 1412–6. doi:10.1023/A:1018955126402
8. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
9. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
10. List of all prohibited substances by WADA – https://www.wada-ama.org/en/
NOTE: These products are intended for laboratory research use only. CJC-1295 (Does not contain DAC) & Ipamorelin for sale is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
